A series of new azaspiro bicyclic hydantoin derivatives has been designed and synthesized. Initially, the anti-proliferative effect of the hydantoin derivatives was evaluated against human ovarian cancer cells (SKOV-3 and OVSAHO) and murine osteosarcoma cells (LM8 and LM8G7). Among the tested compounds,
a b s t r a c t
A series of new azaspiro bicyclic hydantoin derivatives has been designed and synthesized. Initially, the anti-proliferative effect of the hydantoin derivatives was evaluated against human ovarian cancer cells 0 -imidazolidine]-2 0 ,5 0 -dione (7i) showed a significant anti-proliferative activity against the OVSAHO and LM8G7 cells. The real-time monitoring of the effect of the compounds 7h and 7i against the proliferation of LM8G7 was revealed that resulting IC 50 values were 102 lM and 13 lM, respectively. We reasoned that the presence of fluorine atom at the 3rd position of the phenyl ring of the hydantoin side chain may determine the potency of the molecule. Furthermore, the compound 7i inhibited the tube formation of the mouse endothelial cells. Finally, the treatment of the compound 7i against the proliferation of LM8G7 cells demonstrated the down regulation of the secretion of VEGF, indicate the potential angioinhibitory effects. In conclusion, our findings demonstrate the suppression of the secretion of VEGF by LM8G7 cells by the compound 7i might contribute at least in part to the antitumor action.
Ó 2009 Elsevier Ltd. All rights reserved.
Introduction
With a limited improvement in diagnosis, surgical techniques, patient care, and adjuvant therapies, most of the death from cancer is due to metastases. 1 When cancer has metastasized, it may be treated with radiosurgery, chemotherapy, radiation therapy, biological therapy, hormone therapy, or a combination of these. Mainly, the macroscopic growth of tumor masses requires not only tumor cell proliferation but also concomitant angiogenesis. 2 Angiogenesis has been described as one of the hallmarks of cancer. 3 The stimuli that promote tumor angiogenesis may be provided directly by the tumor cells themselves or indirectly by host inflammatory cells that are attracted to the tumor site. Endothelial cell activation and proliferation is regulated by multiple proangiogenic factors, of which the most widely studied is vascular endothelial growth factor (VEGF). VEGF, a potent endothelial cell mitogen in vivo whose function is critical for angiogenesis in both normal development and in tumour cell expansion and invasion. 4, 5 Thus, the inhibition of tumor angiogenesis affords attractive targets for the development of novel antitumor agents. The present invention is to explore the effect of novel hydantoin derivatives on the proliferation of human ovarian tumor cells such as SKOV-3, OVSAHO and as well as murine osteosarcoma cells like LM8 and LM8G7, which have metastatic potential to lung and liver, respectively. 6 Hydantoin lesions have been demonstrated to be highly mutagenic both in vitro and in vivo. 7 The derivatives of hydantoin have attracted much interest in drug discovery because of their wide range of biological activities and therapeutic applications depending on the nature of substitution on the hydantoin ring. 8 In continuation of our ongoing research, 9 herein we report the antitumor and antiangiogenic activity for the newly synthesized compounds 7 (a-i).
The possible mechanism for the anti-tumor activity was examined under in vitro condition.
Results

Chemistry
The synthetic pathway utilized in the preparation of the azaspiro bicyclic hydantoin derivatives is outlined as shown in Scheme 1. A variety of combinatorial approaches have been described by which pharmacophoric groups were attached to such a relatively rigid scaffold. The synthesis begins with the protection of 8-azabicyclo[3.2.1]octan-3-one 1 with Boc anhydride using dry THF as a solvent. Under Bucherer-Bergs condition, 10 construction of azaspiro bicyclic hydantoin ring 3 was made. The reaction was carried out in aqueous ethanolic media by using potassium cyanide and ammonium carbonate at reflux temperature. The introduction of the substituted alkyl/aryl groups at N-3 position of hydantoin ring was achieved via selective N-alkylation reaction by reacting alkyl/ aryl halides in presence of K 2 CO 3 and DMF solvent. Target key intermediates 5 (a-c) was accomplished by deprotection of Boc group from the compound 4 (a-c) with ether in HCl and followed by basification with NaHCO 3 solution. The aim of the fifth step was to introduce respective fluoro substituted aryl halides at the 8th position of azaspiro bicyclic moiety to lead the desired compounds 7 (a-i) for SAR study (Table 1 ). This was furnished by normal condensation reaction with good yield. The formation of the hydantoin ring was confirmed by 1 H NMR and IR spectra.
Biology
2.2.1. Effects of hydantoin derivatives against the proliferation of normal and tumor cells The anti-proliferative activity of hydantoin derivatives 7 (a-i) against four adherent tumor cells was studied. The inhibitory effects of the compounds 7 (a-i) against the human ovarian tumor cells like SKOV-03 and OVSAHO are summarized ( Figs. 1 and 2) . Similarly, the inhibitory effects of the compounds 7 (a-i) against the murine osteosarcoma cells such as LM8 and LM8G7 are summarized (Figs. 3 and 4) . Among the tested compounds, 7h and 7i were significantly inhibited the proliferation of tumor cells. Further, we dynamically monitored the effects of the compound 7h or 7i on the proliferation of LM8G7 cells using RT-CES . Therefore, the above results indicated that the compound 7i markedly inhibits the growth of tumor cells. The cytotoxicity of the compounds 7 (a-i) were tested using mouse endothelial cells (Fig. 5 ).
The compound 7i inhibits angiogenesis in vitro
Since the compound 7i showed anti-tumor activity, we tested the anti-angiogenic effects of compound 7i using an in vitro angiogenesis model. The cultured mouse endothelial cells (40,000 cells/ well) on Matrigel TM in the presence of DMSO (0.1%) and VEGF (2 ng/mL) rapidly align and form a hollow tube like structures (Fig. 8A ). Compound 7i selectively inhibited the tube formation ) cells were cultured in 6-well plates for 24 h. Then the cells were treated with or without the compound 7i at various concentrations. After 48 h, the cells supernatant was taken, centrifuged, and estimated the protein content. Using the known amount of protein, the VEGF content in the cells supernatant was measured. Compound 7i inhibited the secretion of VEGF in a dosedependent manner (Fig. 9) . Compound 7i at 56, 102 and 204 lM effectively inhibited the secretion of VEGF by 23.8%, 46.7% and 63.9%, respectively.
Discussion
The inhibitory effects of hydantoin derivative on the proliferation of tumor cells were compared with cisplatin and mifepristone. The anti-proliferative activity of 7i is considerably higher than the activity of all other hydantoin derivatives tested. The experiment clearly demonstrates the presence of 4-methylsulfonyl benzyl group and 3,4-difluoro benzene moiety, which has an influence on the anti-proliferative activity of hydantoin derivatives. The real-time monitoring of the effect of the compound 7i against the proliferation of LM8G7 cells confirms the potency of the molecule.
Further, VEGF is considered to be one of the major stimulators of tumor angiogenesis. 13 The compound 7i was evaluated for its ability to inhibit angiogenesis in vitro. Endothelial cells (UV$2) are induced to undergo tube formation and form cell-cell contacts that lead to branched networks, which are similar to capillary-like blood vessels. However, when UV$2 cells were cultured on polymerized Matrigel TM in the presence of 7i (50 lM), the cells failed to organize into capillary-like structures. At these concentrations no other compounds tested inhibited tube formation. In order to understand the mechanism of action, the compound 7i, was treated with LM8G7 cells at different concentration to check its effects on the secretion of VEGF. The compound 7i effectively inhibited the secretion of VEGF in a dose-dependent manner. These results indicate that the compound 7i might be inhibited the growth factor-induced proliferation of LM8G7 cells.
Conclusion
In conclusion, our current findings are consistent with the data concerning the inhibitory effects of the compound 7i on the growth of human/mouse tumor cells. Further, the compound 7i inhibited the tube formation of UV$2 cells. Treatment with compound 7i demonstrated the down regulation of the secretion of VEGF in LM8G7 cells indicating the potential angioinhibitory effect of the compound. In conclusion, our findings demonstrate the suppression of the secretion of VEGF by LM8G7 cells might contribute at least in part to the antitumor action of compound 7i. However, further experimental study and preclinical trials could be useful to fully elucidate mechanism of their anti-proliferative action and possible pharmacological strategy for the future treatment of patients with osteosarcoma cancer.
Experimental
Melting points were determined using SELACO-650 hot stage melting point apparatus and were uncorrected. Infrared (IR) spectra were recorded using a Jasco FTIR-4100 series. Nuclear magnetic resonance ( 1 H NMR) spectra were recorded on Shimadzu AMX 297 mmol) and Boc anhydride (25.9 g, 119 mmol) were added. The reaction mixture was allowed to stirred at room temperature for 6 h. were taken in ethanol and water. Then potassium cyanide (16.4 g, 252 mmol) dissolved in water and it was added the above solution. The reaction mixture was refluxed for 40 h. The progress of the reaction was monitored by TLC. Upon completion, the reaction mixture was filtered and washed with water to get hydantoin product 3 in good yield (76%, 18.8 g).
Synthesis of tert-butyl
0 -imidazolidine]-8-carboxylate 3 (2.0 g, 6.77 mmol) in dimethyl formamide was taken, anhydrous K 2 CO 3 (2.8 g, 20.30 mmol) and 1-(bromomethyl) benzene 3a (1.15 g, 6.77 mmol) were added to the solution. The reaction mixture was stirred at room temperature for 7 h and progress of the reaction was monitored by TLC. Upon completion, the solvent was removed under reduced pressure and residue was taken in water and extracted with ethyl acetate. Finally water wash was given to the organic layer and dried with anhydrous Na 2 SO 4 . The solvent was evaporated, crude product was purified by column chromatography over silica gel (60-120 mesh) using chloroform/methanol (9:1) as an eluent (80%, 2.0 g).
The general experimental procedure described above afforded 4b (1.7 g) from tert-butyl 2 0 ,5
0 -imidazolidine]-8-carboxylate 3 (2.0 g, 6.77 mmol), 3-bromoprop-1-ene (0.98 g, 8.12 mmol) and K 2 CO 3 (2.8 g, 20.3 mmol).
The general experimental procedure described above afforded 4c (2.26 g) from tert-butyl 2 0 ,5
0 -imidazolidine]-8-carboxylate 3 (2.0 g, 6.77 mmol), 1-(bromomethyl)-4-(methylsulfonyl)benzene (1.68 g, 6.77 mmol) and K 2 CO 3 (2.8 g, 20.3 mmol).
Synthesis of 1
Compound 4a was taken in dry MDC, cooled to 0°C. Ether in HCl was added and allowed to stirred at room temperature for 3 h. Deprotected salt compound was basified with NaHCO 3 solution and extracted with ethylacetate, organic layer was concentrated to get 5a. Similar experimental procedure was followed for the compounds 5b and 5c. 3 (0.48 g, 3. 5 mmol) was added to the solution and stirred for 10 min 1-(bromomethyl)-4-fluorobenzene 6a (0.13 g, 0.70 mmol) was added. The reaction mixture was stirred at room temperature for 8 h and progress of the reaction was monitored by TLC. Upon completion, the solvent was removed under reduced pressure and residue was taken in water and extracted with ethyl acetate. Finally water wash was given to the organic layer and dried with anhydrous Na 2 SO 4 .The solvent was evaporated, crude product was purified by column chromatography over silica gel (60-120 mesh) using chloroform/methanol (9:1) as an eluent to get 7a (0.22 g) as pale yellow crystalline solid. 1 
The general experimental procedure described above afforded 7g, the product obtained (0.20 g) was off-white crystalline solid from 5.6.9. Synthesis of 8- (3,4- 
The general experimental procedure described above afforded 7i, the product obtained (0.195 g) was off-white crystalline solid from 1 0 -(4-(methylsulfonyl)benzyl)- ) cells were seeded into a 6-well plates and incubated overnight. After 24 h, the media was replaced with fresh serum-free medium containing 56 lM, 102 lM, and 204 lM of compound 7i. The cells were further incubated for 48 h at 37°C. The cell supernatant was collected, centrifuged at 5000 rpm for 5 min at 4°C and the protein concentrations were determined by BCA (bicinchoninic acid) assay kit (Thermo Fisher Scientific Inc. USA). 15 The quantification of the mouse VEGF was done using the Immuno Assay Kit (Quantikine, R&D systems). Briefly, the known amount of recombinant VEGF as standard and the samples to be tested were added to a 96-well microplate, which was precoated with the polyclonal antibody specific for mouse VEGF and incubated for 2 h. The bound VEGF was detected by adding horseradish peroxidase conjugated polyclonal antibody against mouse VEGF. After 2 h, the substrate chromogen was added and allowed to react for 30 min with the peroxidase conjugate, the reaction was stopped and the VEGF content was quantified in a micro-plate reader at 450 nm (BIORAD, Model 680). The decrease in the amount of VEGF secretion by the compound 7i was presented.
